A peptoid antagonist of VEGF Receptor 2 recognizes a 'hotspot' in the extracellular domain distinct from the hormone-binding site

Department of Internal Medicine, Division of Translational Research, University of Texas Southwestern Medical Center, Dallas, TX 75390-9185, USA.
Bioorganic & medicinal chemistry (Impact Factor: 2.79). 07/2008; 16(12):6338-43. DOI: 10.1016/j.bmc.2008.05.015
Source: PubMed


Antagonists of VEGF-mediated angiogenesis are of great interest clinically for the treatment of solid tumors and certain forms of macular degeneration. We recently described a novel peptoid antagonist of VEGF Receptor 2 (VEGFR2) that binds to the extracellular domain of the receptor and inhibits VEGF-mediated autophosphorylation and subsequent downstream signaling. Given the structural similarities between peptides and peptoids, an obvious model for the mode of action of the peptoid is that it competes with VEGF for binding to VEGFR2. However, we present evidence here that this is not the case and that VEGF and the peptoid antagonist recognize non-overlapping surfaces located within the first three immunoglobulin-like subdomains of the receptor. These data argue that the peptoid inhibits receptor-mediated autophosphorylation by a novel allosteric mechanism that may prevent the receptor from acquiring the conformation necessary to propagate downstream signals.

Download full-text


Available from: Rolf A Brekken,
  • Source
    • "Only five of the approximately 300,000 beads screened (approximately 0.0017% of the population) were observed to bind PAE/KDR (redstained ) cells alone (Fig. 2) indicating those bound through VEGFR2. In subsequent validation experiments, we found that all five of these peptoids bind to a single 'hot spot' on the VEGFR2 surface (Udugamasooriya et al., 2008c). We have dimerized one of those compounds to display strong anti-angiogeic properties both in vitro and in vivo mice models (Astle, 2008; Lynn et al., 2010; Roland et al., 2009; Udugamasooriya et al., 2008a; Udugamasooriya et al., 2008b) as well as attached Gd(III) based contrast agents to image VEGF receptors at the cellular level and in vivo mice models using MRI (De Leon- Rodriguez et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Combinatorial library screens can identify a suitable ligand for a biological target of interest out of thousands or even millions of compounds, and can play a key role in the modern drug development process. While conventional high-throughput cell screens based on functional assays require expensive robotics, simple on-bead combinatorial assays for ligand binding to the target protein can be done far more cheaply. This article describes one such assay, developed using combinatorial peptoid libraries for targeting integral membrane receptors or other cell surface-exposed molecules. In addition to the reduced cost, a unique advantage of this assay is the direct identification of the most selective ligands for a cell surface receptor that is expressed in its natural environment.
    03/2012; 4:35-48. DOI:10.1002/9780470559277.ch110199
  • Source
    • "The hybridoma producing RAFL-2, a rat IgG specific for VEGFR2 was obtained from Dr. Philip Thorpe and was produced and purified in our laboratory as described [55]. GU81, a peptoid that binds and specifically inhibits VEGFR1 and VEGFR2 was produced as described previously [56], [57], [58], [59]. Sunitinib, a receptor tyrosine kinase inhibitor which inhibits VEGFR1, VEGFR2, PDGFRβ, c-kit, Flt-3, and c-Ret was purchased from LC laboratories (Woburn, MA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The effect of blocking VEGF activity in solid tumors extends beyond inhibition of angiogenesis. However, no studies have compared the effectiveness of mechanistically different anti-VEGF inhibitors with respect to changes in tumor growth and alterations in the tumor microenvironment. In this study we use three distinct breast cancer models, a MDA-MB-231 xenograft model, a 4T1 syngenic model, and a transgenic model using MMTV-PyMT mice, to explore the effects of various anti-VEGF therapies on tumor vasculature, immune cell infiltration, and cytokine levels. Tumor vasculature and immune cell infiltration were evaluated using immunohistochemistry. Cytokine levels were evaluated using ELISA and electrochemiluminescence. We found that blocking the activation of VEGF receptor resulted in changes in intra-tumoral cytokine levels, specifically IL-1beta, IL-6 and CXCL1. Modulation of the level these cytokines is important for controlling immune cell infiltration and ultimately tumor growth. Furthermore, we demonstrate that selective inhibition of VEGF binding to VEGFR2 with r84 is more effective at controlling tumor growth and inhibiting the infiltration of suppressive immune cells (MDSC, Treg, macrophages) while increasing the mature dendritic cell fraction than other anti-VEGF strategies. In addition, we found that changes in serum IL-1beta and IL-6 levels correlated with response to therapy, identifying two possible biomarkers for assessing the effectiveness of anti-VEGF therapy in breast cancer patients.
    PLoS ONE 11/2009; 4(11):e7669. DOI:10.1371/journal.pone.0007669 · 3.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peptoids are peptidomimetic oligomers composed of N-substituted glycine units. Their convenient synthesis enables strict control over the sequence of highly diverse monomers and is capable of generating extensive compound libraries. Recent studies are beginning to explore the relationship between peptoid sequence, structure and function. We describe new approaches to direct the conformation of the peptoid backbone, leading to secondary structures such as helices, loops, and turns. These advances are enabling the discovery of bioactive peptoids and will establish modules for the design and assembly of protein mimetics.
    Current opinion in chemical biology 10/2008; 12(6):714-21. DOI:10.1016/j.cbpa.2008.08.015 · 6.81 Impact Factor
Show more